Adarx Pharmaceuticals Q3 EPS $(1.74) Misses $(0.31) Estimate, Sales $2.200M Miss $2.583M Estimate
Benzinga Newsdesk 3 days ago
NewsEarningsEarnings Misses
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Adarx Pharmaceuticals (NASDAQ:ADRX) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(0.31) by 461.29 percent. This is a 5.95 percent increase over losses of $(1.85) per
Adarx Pharmaceuticals (NASDAQ:ADRX) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(0.31) by 461.29 percent. This is a 5.95 percent increase over losses of $(1.85) per share from the same period last year. The company reported quarterly sales of $2.200 million which missed the analyst consensus estimate of $2.583 million by 14.84 percent. This is a 41.94 percent increase over sales of $1.550 million the same period last year.
